Cytokinetics news and milestones

Cytokinetics stock traded at USD 66.05 on September 28, 2026, while second-quarter revenue reached USD 28.6 million. Myqorzo sales rose to USD 25.3 million.

Cytokinetics (NASDAQ:CYTK) executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor s…

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for

Cytokinetics stock is trading on Nasdaq around recent levels as of September 19, 2026, after the company updated investors on trial progress and guidance in its latest quarterly…

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, ...

Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular DiseasesDeadline for Application...

Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintain…

Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date.

--Cytokinetics, Incorporated today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible seni…